Mecasermin

In the US, Mecasermin (mecasermin systemic) is a member of the drug class insulin-like growth factor and is used to treat Primary IGF-1 Deficiency.

US matches:

• Mecasermin


• Mecasermin rinfabate


• Mecasermin Subcutaneous

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

H01AC03

CAS registry number (Chemical Abstracts Service)

0068562-41-4

Chemical Formula

C331-H512-N94-O101-S7

Molecular Weight

7648

Therapeutic Categories

Antidiabetic agent

Growth factor

Chemical Name

Insulin-like growth factor I (human) (WHO)

Foreign Names

• Mecaserminum (Latin)
• Mecasermin (German)
• Mécasermine (French)
• Mecasermina (Spanish)

Generic Names

• Mecasermin (OS: JAN, BAN, USAN)
• Mécasermine (OS: DCF)
• CCRIS 6804 (IS)
• CEP-151 (IS)
• FK 780 (IS)
• IGF-I (IS)
• Insulin-like growth factor I (human) (IS: WHO)
• rDNA IGF-1 (IS)
• rhIGF-1 (IS)
• Somatomedin C human (IS: genetical recombination)
• Mecasermin Rinfabate (OS: USAN)

Brand Names

• Increlex
  Ipsen, Belgium; Ipsen, Germany; Ipsen, Denmark; Ipsen, Spain; Ipsen, France; Ipsen, United Kingdom; Ipsen, Ireland; Ipsen, Italy; Tercica, Austria; Tercica, Greece; Tercica, Netherlands



• INCRELEX
  IPSEN, Sweden



• Somazon
  Astellas, Japan



• Increlex
  Tercica, United States

International Drug Name Search

Glossary

BAN	British Approved Name
DCF	Dénomination Commune Française
IS	Inofficial Synonym
JAN	Japanese Accepted Name
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.